News

Cytovation and SMS-oncology sign agreement on conduct of phase I/II trial with CyPep-1 in solid tumors

08/08/2019

Bergen, Norway and Schiphol, the Netherlands (8 August 2019) – Cytovation AS (“Cytovation”) and Specialized Medical Services-oncology BV (“SMS-oncology”) today…

Cytovation initiates clinical development programme with CyPep-1,a first-in-class lytic agent for tumor immunotherapy

18/03/2019

BERGEN, NORWAY, 18 March 2019 – Cytovation AS, a privately held biotech company, announces that the first patients have been…

Cytovation completes NOK 30m financing round to progress CyPep-H1 through Phase I/IIa clinical study in cutaneous warts

18/01/2018

BERGEN, NORWAY, 8th January 2018 – Cytovation AS, a privately held biotech company developing CyPep-H1 for the treatment of cutaneous warts,…

Cytovation announces private fundraising round of NOK 20m to progress CyPep-1 to Phase 1 clinical study

29/07/2017

BERGEN, NORWAY, 29th June 2017 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin…

Cytovation announces appointment of Ole-Erik Iversen as Scientific Advisor

20/01/2017

BERGEN, NORWAY, 20 January 2017 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin…

Cytovation announces two key appointments to the management team

03/10/2016

BERGEN, NORWAY, 3rd October 2016 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disease, announces the…

Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts

01/07/2016

Bergen, Norway – July 2016 – Cytovation, focused on the treatment of dermatological diseases, announced that it has been granted a…

Cytovation welcomes new CEO

01/09/2014

BERGEN, NORWAY, 1 September 2014 – Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disease,…